Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. (Nasdaq: ARDX) is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that address significant unmet medical needs. The company's mission is to enhance the treatment of renal and gastrointestinal diseases through its proprietary drug discovery and design platform.
One of Ardelyx's lead products is tenapanor, which has been developed to reduce the absorption of dietary sodium and phosphorus. It is being investigated for multiple conditions, including hyperphosphatemia in patients with end-stage renal disease on dialysis and irritable bowel syndrome with constipation (IBS-C). The company has made significant strides in these areas, recently gaining FDA approval for tenapanor under the brand names IBSRELA® and XPHOZAH®. IBSRELA is targeted at treating IBS-C, while XPHOZAH is aimed at controlling serum phosphorus levels in patients with chronic kidney disease on dialysis.
Ardelyx has also forged strategic partnerships to extend the reach of its therapies globally. This includes collaborations with Kyowa Kirin in Japan, Fosun Pharma in China, and Knight Therapeutics in Canada. Notably, Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan, while a New Drug Application for the same indication is under review in China.
In its latest financial update, Ardelyx reported strong revenue growth for IBSRELA, achieving approximately $80 million in net product sales revenue for its first full year of commercialization. The company anticipates even higher sales in 2024, projecting revenues between $140 million and $150 million. Additionally, XPHOZAH, which launched in November 2023, recorded $2.5 million in net product sales revenue in its first quarter. To support these products, Ardelyx is investing in expanding its sales team and digital capabilities, as well as enhancing its patient services through the ArdelyxAssist™ program.
As of December 31, 2023, Ardelyx maintained a strong cash position with approximately $184 million in cash, cash equivalents, and short-term investments. The company’s financial stability and continuous investment in its robust R&D pipeline underscore its commitment to advancing the standard of care for patients with renal and gastrointestinal diseases.
Ardelyx continues to engage with the medical community and investors through various platforms, including regular webcasts and conferences. The company remains focused on executing its commercial strategy, expanding market penetration, and exploring new avenues for growth through internal development and external partnerships.
Ardelyx, Inc. (NASDAQ: ARDX) announced a conference call to discuss its first quarter financial results and provide a business update on May 3, 2023, at 4:30 p.m. ET. The call can be accessed by dialing (844) 481-2838 domestically or (412) 317-1858 internationally, with a live audio webcast available on the company’s website. Ardelyx is committed to developing first-in-class medicines for unmet medical needs, having achieved success with its approved product IBSRELA® (tenapanor). Additionally, the company is advancing XPHOZAH® for chronic kidney disease patients and has multiple collaborations in place with international partners for the commercialization of tenapanor. More details can be found on Ardelyx's website.
Ardelyx, Inc. (Nasdaq: ARDX) has announced the resubmission of a New Drug Application (NDA) for XPHOZAH (tenapanor) targeting serum phosphate control in adults with chronic kidney disease (CKD) on dialysis. This NDA supports over 1,200 patients' data from three successful Phase 3 trials and two Phase 4 trials, all meeting critical endpoints. Confirmation of the resubmission's completeness from the FDA is anticipated by mid-May. XPHOZAH functions as a phosphate absorption inhibitor, requiring a simple dosing regimen of one 30mg tablet twice daily. Hyperphosphatemia, affecting many CKD patients, underscores the drug's potential significance. Ardelyx continues to pursue innovative treatments for unmet medical needs.
Ardelyx, Inc. (Nasdaq: ARDX) announced on April 10, 2023, that its compensation committee granted stock options and Restricted Stock Units (RSUs) to seven new non-executive employees. A total of 238,426 shares in stock options and 89,250 RSUs were awarded, with the exercise price set at $4.26 per share, corresponding to the company's closing stock price on the grant date. The stock options will vest over four years, while the RSUs will also vest over the same period, with varying percentages vesting at specified intervals. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) and is intended to incentivize new employees.
Ardelyx is focused on developing innovative medicines, including its FDA-approved product IBSRELA and ongoing studies for its candidates targeting kidney-related health issues.
Ardelyx, Inc. (Nasdaq: ARDX) announced positive clinical findings for XPHOZAH at the National Kidney Foundation 2023 Spring Clinical Meetings. XPHOZAH, a novel phosphate absorption inhibitor, demonstrated efficacy in lowering serum phosphate levels in patients with chronic kidney disease (CKD) on maintenance dialysis. Data from three Phase 3 pivotal trials showed that XPHOZAH reduced serum phosphate consistently across diverse patient demographics, with results comparable to sevelamer. Additionally, XPHOZAH effectively lowered elevated fibroblast growth factor 23 (iFGF23) levels. Notably, the medication's dosing regimen of one tablet twice daily reduces pill burden for patients. The most common adverse effect reported was diarrhea, consistent with previous studies.
Ardelyx, Inc. reported a successful year for 2022, highlighted by $15.6 million in net product sales for its IBS treatment, IBSRELA. The company ended Q4 2022 with $123.9 million in cash and investments. Ardelyx announced plans to resubmit the XPHOZAH New Drug Application in early Q2 2023, following favorable discussions with the FDA. Collaboration revenue surged to $36.6 million, a significant increase from $10.1 million in 2021. However, the company recorded a net loss of $67.2 million for 2022, an improvement from the previous year's loss of $158.2 million. Ardelyx continues to focus on expanding its product offerings and achieving growth in 2023.
Ardelyx, Inc. (Nasdaq: ARDX) announced participation by CEO Mike Raab in a GI/Microbiome panel at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 9:10 A.M. ET in Boston, MA. The event will be accessible via a live webcast on the Ardelyx website.
Ardelyx focuses on developing innovative medicines addressing unmet medical needs. Its products include IBSRELA (tenapanor) and XPHOZAH (for chronic kidney disease), which has completed three Phase 3 trials. Ardelyx collaborates with Kyowa Kirin, Fosun Pharma, and Knight Therapeutics for product development globally.
Ardelyx, Inc. (Nasdaq: ARDX) announced a conference call on March 2, 2023, at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2022 financial results and provide a business update. The call will be accessible via phone or webcast, with an archive available for 30 days after. Ardelyx is focused on developing innovative medicines for unmet medical needs, including its first product, IBSRELA® (tenapanor), and other candidates like XPHOZAH® and RDX013. The company has established international agreements for tenapanor's development and commercialization.
On January 27, 2023, Ardelyx, Inc. (Nasdaq: ARDX) granted stock options and Restricted Stock Units (RSUs) to 23 new non-executive employees. The total awarded includes 614,064 stock options with an exercise price of $2.85, matching the closing price on the grant date, and 236,333 RSUs. The stock options vest over four years, with 25% vesting on the first anniversary and the rest monthly. The RSUs follow a similar vesting schedule, with 25% vesting on the first quarterly RSU date after the first anniversary. These grants were made as inducements to attract new talent in accordance with Nasdaq rules.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
What is Ardelyx, Inc. focused on?
What are the main products of Ardelyx?
How has Ardelyx performed financially in recent years?
What strategic partnerships does Ardelyx have?
What is tenapanor used for?
What is the ArdelyxAssist™ program?
What is the financial status of Ardelyx?
Where can investors find more information about Ardelyx?
What recent achievements has Ardelyx made?
What future plans does Ardelyx have?
